Join Dr. Geo in this episode as he engages in a fascinating conversation with Dr. Rana McKay, a renowned medical oncologist specializing in prostate, bladder, kidney, and testicular cancer. As an associate professor at UC San Diego School of Medicine, Dr. McKay delivers exceptional patient care and imparts her extensive knowledge to medical students, residents, and fellows.
In this enthralling discussion, Dr. Geo and Dr. McKay explore the intricacies of Androgen Deprivation Therapy (ADT), a vital approach in the treatment of prostate cancer. Together, they shed light on the characteristics defining an ideal candidate for ADT and clarify the true nature of advanced prostate cancer.
They uncover valuable insights into the average duration of ADT's effectiveness for men confronting advanced prostate cancer. The conversation also encompasses exploring the various types of ADT, including the intriguing concept of chemical castration. This approach offers significant promise by utilizing medications to lower androgen levels and impede the growth of prostate cancer cells. Furthermore, Dr. Geo and Dr. McKay delve into the fascinating realm of bipolar androgen therapy, an alternative approach that involves carefully calibrated testosterone doses. This discussion challenges conventional wisdom and expands our understanding of the potential benefits of this therapeutic strategy.
Prepare to enrich your knowledge and gain a deeper understanding of the crucial role of androgen deprivation therapy in patients' lives. Join us for an insightful journey with Dr. Rana McKay and Dr. Geo as they explore the intricacies of this essential treatment approach.
__________________
Thank you to our sponsors.
This episode is brought to you by ExoDx™ Prostate Test for prostate tissue. The ExoDx™ Prostate Test is a simple, non-DRE, urine-based, liquid biopsy test indicated for men 50 years of age and older with a prostate-specific antigen (PSA) 2-10ng/mL, or PSA in the “gray zone” who may be considering a biopsy. The ExoDx Prostate test provides a risk score that determines a patient’s potential risk of clinically significant prostate cancer (Gleason Score ≥7). The test is included in the National Comprehensive Cancer Network (NCCN) guidelines and has been clinically validated at the cut-point of 15.6 with a 91% sensitivity and 92% negative predictive value, meaning there is less than a 9% chance of having aggressive prostate cancer below the validated cut-point of 15.6. Ask your urologist about the ExoDx Prostate Test.
This episode is also brought to you by AG1 (Athletic Greens). AG1 contain 75 high-quality vitamins, minerals, whole-food sourced ingredients, probiotics, and adaptogens to help you start your day right. This special blend of ingredients supports your gut health, your nervous system, your immune system, your energy, recovery, focus, and aging. All the things. Enjoy AG1 (Athletic Greens).
----------------
Thanks for listening to this week's episode. Subscribe to The Dr. Geo YouTube Channel to get more content like this and learn how you can live better with age.
You can also listen to this episode and future episodes of the Dr. Geo Podcast by clicking HERE.
----------------
Follow Dr. Geo on social media. Facebook, Instagram Click here to become a member of Dr. Geo’s Health Community.
Improve your urological health with Dr. Geo’s formulated supplement lines: XY Wellness for Prostate cancer lifestyle and nutrition: Mr. Happy Nutraceutical Supplements for prostate health and male optimal living.
You can also check out Dr. Geo’s online dispensary for other supplement recommendations Dr. Geo’s Supplement Store
____________________________________
DISCLAIMER: This audio is educational and does not constitute medical advice. This audio's content is my opinion and not that of my employer(s) or any affiliated company.
Use of this information is at your own risk. Geovanni Espinosa, N.D., will not assume any liability for any direct or indirect losses or damages that may result from the use of the information contained in this video, including but not limited to economic loss, injury, illness, or death.
